Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells / SZGIMI - LARVOL DELTA

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov) - P1/2 | N=10 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Unknown status ➔ Recruiting | Trial completion date: Dec 2020 ➔ Dec 2028 | Trial primary completion date: Dec 2019 ➔ Jun 2028

Enrollment open • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • CD38 • IL3RA • NCAM1